News & Publications

Cyclarity’s one-page company profile now available for download and review.

Cyclarity Therapeutics, Inc.  is proud to present a one-sheet summarizing our approach to curing heart disease, the results we’ve achieved thus far, and the status of our ongoing efforts.

About Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Announcing the release of the NFX original film: THE FUTURE OF LONGEVITY

Announcing the release of the NFX Original film THE FUTURE OF LONGEVITY: The Battle Against Human Aging.

Many thanks and Gratitude to Omri Amirav-Drory and Eric Ward at NFX for creating this documentary featuring scientists making a difference in the field of longevity. We are honored they chose to include Cyclarity Therapeutics ‘ CEO, Scientific Affairs, Matthew “Oki” O’Connor, Head of Scientific Computing, Amelia Anderson and Vice President of Biology, Daniel Clemens.

Based at the Buck Institute for Research on Aging in Novato, California, US, we are working to reverse atherosclerosis. Our mission to provide a drug (UDP-003) that can genuinely modify the course of primary coronary heart disease, peripheral artery disease, and carotid stenosis.

The drug is clinic-ready (in vials and labeled, and the safety package is being finalized). We expect phase 1 to be performed in Australia under the direction of the Victoria Heart Institute in 2024, with a multi-country, multi-site phase 2 in ’25 through ‘27. The company is currently raising a Series A-1 to fund the phase 1 trial.

About Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity Therapeutics Announces Clinical Advisory Board

Press Release

NOVATO, Calif., October 17, 2023 (GLOBE NEWSWIRE)

Cyclarity Therapeutics, Inc.  today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

The Board includes the internationally recognized, preeminent cardiologists:

Dr. Prediman K. Shah, Director of Inpatient Cardiology and the Coronary Care Unit at Cedars-Sinai Hospital, Founder and Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Hospital.

Dr. Michael E. Farkouh, Associate Dean for Research and Clinical Trials and Professor of Cardiology at Cedars-Sinai Hospital.

Dr. Stephen Nicholls, Program Director of MonashHeart, Intensive Care and Victorian Heart Hospital, Monash Health, as well as Director of the Monash Victorian Heart Institute and Professor of Cardiology at Monash University.

“It’s an honor to have Drs. Nicholls, Farkouh and Shah working with us to provide strategic guidance over the preparation and execution of our clinical program,” said Mike Kope, Corporate Affairs CEO of Cyclarity. Cyclarity expects to conduct the UDP-003 Phase 1 trial under the direction of Dr. Nicholls and VHI, and is exploring potential lead site and primary PI roles with Drs. Farkouh and Shah at Cedars-Sinai.

“We are especially encouraged by the interest of this distinguished Board not only in our drug candidate, but in the novel target we are addressing,” noted Matthew O’Connor, Cyclarity’s Scientific Affairs CEO. “Their guidance will provide immeasurable assistance to our evaluation of outcomes and our examination of oxidized cholesterols as causative biomarkers of atherosclerosis.”

About Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Our latest manuscript pre-proof in Carbohydrate Polymers

Pre-proofs are now available for our latest manuscript in Carbohydrate Polymers: “Addressing the complexities in measuring cyclodextrin-sterol binding constants: A multidimensional study”.

Abstract:

Cyclarity Therapeutics has developed a new class of cyclodextrin (CD) dimers as a potential new treatment for atherosclerosis. These CD therapies work by forming strong, soluble inclusion complexes with oxysterols, allowing the body to reduce and heal arterial plaques. However, characterizing the interactions between CD dimers and oxysterols presents formidable challenges due to low sterol solubility, the synthesis of modified CDs resulting in varying number and position of molecular substitutions, and the diversity of interaction mechanisms. To address these challenges and illuminate the nuances of CD-sterol interactions, we have used multiple orthogonal approaches for a comprehensive characterization. Results obtained from three independent techniques – metadynamics simulations, competitive isothermal titration calorimetry, and circular dichroism – to quantify CD-sterol binding are presented. The objective of this study is to obtain the binding constants and gain insights into the intricate nature of the system, while accounting for the advantages and limitations of each method. Notably, our findings demonstrate ~1000× stronger affinity of the CD dimer for 7-ketocholesterol in comparison to cholesterol for the 1:1 complex in direct binding assays. These methodologies and findings not only enhance our understanding of CD dimer-sterol interactions, but could also be generally applicable to prediction and quantification of other challenging host-guest complex systems.

Congratulations to our team and collaborators – great work!

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Dr. Oki O’Connor talks with Phil Newman of Longevity.Technology about Cyclarity’s solution

Watch the Longevity.Technology interview of Dr. Oki O’Connor on “Cyclarity’s elegant solution to one of the world’s biggest problems – atherosclerosis.” 

Dr. O’Connor and Phil Newman discuss:

  • The unique Cyclarity platform.
  • The nature of cyclodextrins.
  • The opportunities in the cyclodextrin market.
  • The size of the problem.

We’re thrilled to be working towards reversing the world’s leading killer and thankful to Longevity.Technology for bringing a focus to our novel treatment.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Congratulations to our talented team on their larger roles in developing cures for heart disease!

Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!

  • Dr. Daniel Clemens: Vice President of Biology
  • Dr. Keivan Sadrerafi: Director of Chemistry
  • Dr. Prerna Bhargava: Senior Scientist
  • Darren Dinh: Senior Research Associate/ Lab Manager

It is through the hard work of our dedicated team that we are able to take on the world’s leading killer!

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

For media inquiries:

For general inquiries:

Cyclarity Therapeutics logos for media use: